Sitemap > Breaking Research > Cardiovascular Disorders
Displaying 51 - 100 of 4862 results
- The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization.
- Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study.
- Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability.
- Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents.
- Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand.
- Structure-activity relationships of potent and selective factor Xa inhibitors: benzimidazole derivatives with the side chain oriented to the prime site of factor Xa.
- Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect?
- Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.
- Mitochondrial uncoupling protein 1 expressed in the heart of transgenic mice protects against ischemic-reperfusion damage.
- Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
- Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.
- Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease.
- Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
- Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
- cAMP protects endothelial barrier functions by preventing Rac-1 inhibition.
- Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning.
- Lower limb arterial incompressibility and obstruction in rheumatoid arthritis.
- Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study.
- Systemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis.
- A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD Study.
- Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases.
- Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.
- Autologous vascular smooth muscle cell-based myocardial gene therapy to induce coronary collateral growth.
- Gene transfer of extracellular superoxide dismutase improves relaxation of aorta after treatment with endotoxin.
- Are we underestimating diabetes-related lower-extremity amputation rates? Results and benefits of the first prospective study.
- Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
- MC-3 receptor and the inflammatory mechanisms activated in acute myocardial infarct.
- Use of antihypertensive agents in the management of patients with acute ischemic stroke.
- Differential expression of adenylyl cyclase subtypes in human cardiovascular system.
- Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms.
- Cytoprotective efficacy and mechanisms of the liposoluble iron chelator 2,2'-dipyridyl in the rat photothrombotic ischemic stroke model.
- Vanin-1-/- mice exhibit a glutathione-mediated tissue resistance to oxidative stress.
- Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.
- A randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in the over 65s: (SAFE) [ISRCTN19633732].
- Experimental Peptide Identification Repository (EPIR): an integrated peptide-centric platform for validation and mining of tandem mass spectrometry data.
- Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model.
- Bone marrow-derived immune cells regulate vascular disease through a p27(Kip1)-dependent mechanism.
- In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery.
- Novel diacylglycerol kinase inhibitor selectively suppressed an U46619-induced enhancement of mouse portal vein contraction under high glucose conditions.
- Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
- Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
- Protection of transplant-induced renal ischemia-reperfusion injury with carbon monoxide.
- Efficacy and tolerability of manidipine in the treatment of hypertension in patients with non-diabetic chronic kidney disease without glomerular disease. Prospective, randomized, double-blind study of parallel groups in comparison with enalapril.
- pH-triggered microparticles for peptide vaccination.
- Inhibition of PLC improves postischemic recovery in isolated rat heart.
- Small interfering RNA-induced transcriptional gene silencing in human cells.
- Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques.
- Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody.
- Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
- Employing tumor hypoxia to enhance oncolytic viral therapy in breast cancer.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 Next >